INDEX3

Dr. Irene Gonzalez presented Valens' platform technology of molecules for neurology and inflammation in Cambridge, Boston, MA on November 16, 2011 upon invitation by UBIFRANCE.
http://frenchbiotechtour.ubifrance-events.com/

Dr. Irene Gonzalez presented Valens' platform technology of molecules for infectious diseases at the MIT in Boston, MA on September 21, 2011 upon invitation by UBIFRANCE.

Dr. Irene Gonzalez presented Valens' platform technology of molecules for oncology at the Oncology Network of the European Cancer Cluster in Tolouse, France on September 15th, 2011.

Dr. Irene gonzalez received a grant award from the Maryland Department of Business and Economic Development to participate in the delegation of MD companies to the European Cancer Cluster Partnering event in Tolouse, France, September 14-16, 2011.
http://www.emarketingmd.org/pubs/globalpulse/2011-09-06/story2.htm

Dr. Irene Gonzalez presented recent advances of Valens's HIV therapeutic vaccine in the breakout session Innovations in Vaccines at the 2011 Bio International Convention on June 29 in Washington, DC. http://mybio.zerista.com/event/member?item_id=1100565

Dr. Irene Gonzalez presented a seminar on Drug Delivery Systems for the Patent Examiner Technical Training Program upon invitation by the USPTO on May 19th, 2011.

Dr. Irene Gonzalez was a nominee and finalist in the Entreprenurial Spirit Award category of the Greater Baltimore Committee, 6th Annual Maryland Bioscience Awards on March 29, 2011 in Baltimore, MD.

Valens Therapeutics receives private investment to advance the development of its proprietary molecules for pancreatic cancer.

Valens Therapeutics files utility and PCT patents with USPTO for its Oncology, Ophtalmology, Infectious Diseases, and Neurology molecules.

Valens Therapeutics participated in The Equity Matters in Washington DC. Dr. Irene Gonzalez presented to DC investors Valens' Platform Technology

Dr. Irene Gonzalez presented Valen's commercially relevant emerging technologies and next-generation medical solutions for human healthcare at the Life Sciences Summit 2010 in November in Long Island New York.

Valens Therapeutics names Dr. Richard Thorn as Chief of Product Development and Manufacturing.

Valens Therapeutics files utility and PCT patents for its HIV molecules with USPTO.

Valens Therapeutics receives private investment to continue development of its proprietary molecules.

Valens Therapeutics completes creation of its proprietary platform technology that includes molecules for ocular, oncology, infectious diseases, and neurology.

Valens Therapeutics receives a private investment to initiate development of its Platform Technology.

Valens Therapeutics joins the bwtech@UMBC Technology Center in May. The company is developing novel next-generation multi-targeted therapies for human diseases